10/ 581,279

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 4	APR 07	STN is raising the limits on saved answers
NEWS 5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7	APR 28	CAS patent authority coverage expanded
NEWS 8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS 10	MAY 08	STN Express, Version 8.4, now available
NEWS 11	MAY 11	STN on the Web enhanced
NEWS 12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS 13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:48:53 ON 09 JUN 2009

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY 0.22 TOTAL SESSION 0.22
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 11:48:59 ON 09 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 7 JUN 2009 HIGHEST RN 1153571-52-8
DICTIONARY FILE UPDATES: 7 JUN 2009 HIGHEST RN 1153571-52-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10581279.str



chain nodes :
11 21 22 23 24 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20 29 30 31 32
33
chain bonds :
5-24 6-23 7-11 11-12 17-21 19-22 23-25 24-26 26-27 27-28 28-29
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 15-18 16-17 16-20 18-19 19-20 29-30 29-33 30-31 31-32 32-33
exact/norm bonds :
5-24 6-23 7-11 11-12 15-18 18-19 19-22 23-25 24-26 28-29
exact bonds :

16-20 17-21 19-20 26-27 27-28 29-30 29-33 30-31 31-32 32-33
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 : 29 :

Hydrogen count :
9:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 11:49:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 208 TO ITERATE

100.0% PROCESSED 208 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

L2 18 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 185.88 186.10

FILE 'CAPLUS' ENTERED AT 11:49:35 ON 09 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

FILE COVERS 1907 - 9 Jun 2009 VOL 150 ISS 24
FILE LAST UPDATED: 8 Jun 2009 (20090608/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 93 L2

=> s l3 and maleate
33389 MALEATE
L4 2 L3 AND MALEATE

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:552352 CAPLUS
DOCUMENT NUMBER: 148:517536
TITLE: Process for preparation of 4-fluoro-2-methyl-1H-indol-5-ol from fluorohalonitrobenzenes and acetoacetate esters.
INVENTOR(S): Arnott, Euan Alexander; Crosby, John; Evans, Matthew Charles; Ford, James Gair; Jones, Martin Francis; Leslie, Kevin William; Mcfarlane, Ian Michael; Sependa, George Joseph
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008053221	A2	20080508	WO 2007-GB4176	20071101

WO 2008053221 A3 20081231
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
US 20080221322 A1 20080911 US 2007-931599 20071031
AU 2007315982 A1 20080508 AU 2007-315982 20071101
PRIORITY APPLN. INFO.: US 2006-864036P P 20061102
US 2007-957401P P 20070822
WO 2007-GB4176 W 20071101
OTHER SOURCE(S): CASREACT 148:517536; MARPAT 148:517536
GI



AB 4-Fluoro-5-hydroxy-2-methyl-1H-indole was prepared by reaction of fluoronitrobenzenes [I; R1, R2 = Cl, Br, F, iodo, (substituted) alkylsulfonyloxy] with MeCOCH2CO2R3 (R3 = esterifying group) to give coupling products (II; variables as above) followed by hydroxylation with OH- in the presence of aralkylammonium or tetraalkylammonium salts to give phenols (III; R3 as above) followed by decarboxylation and reductive cyclization. The product was used to prepare AZD2171.
IT 288383-20-0P, AZD2171 857036-77-2P, AZD 2171 maleate
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fluoromethylindolol from fluorohalonitrobenzenes and acetoacetate esters)
RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 857036-77-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:588947 CAPLUS
DOCUMENT NUMBER: 143:103197
TITLE: Maleate salts of a quinazoline derivative used as an antiangiogenic agent
INVENTOR(S): McCabe, James
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061488	A1	20050707	WO 2004-GB5359	20041218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303590	A1	20050707	AU 2004-303590	20041218
CA 2548662	A1	20050707	CA 2004-2548662	20041218
EP 1699782	A1	20060913	EP 2004-806159	20041218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN 1898232	A	20070117	CN 2004-80038665	20041218
BR 2004017958	A	20070327	BR 2004-17958	20041218
JP 2007517008	T	20070628	JP 2006-546311	20041218
US 20070129387	A1	20070607	US 2006-581279	20060601
MX 2006007191	A	20060823	MX 2006-7191	20060622
ZA 2006005225	A	20070530	ZA 2006-5225	20060623
IN 2006MN00832	A	20070413	IN 2006-MN832	20060714
KR 2006127899	A	20061213	KR 2006-714753	20060721

PRIORITY APPLN. INFO.:		
GB 2003-30002	A	20031224
WO 2004-GB5359	W	20041218

AB The present invention relates to AZD2171 maleate salt, to particular crystalline forms of AZD2171 maleate salt, to processes for their preparation, to pharmaceutical compns. containing them as active ingredient, to their use in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to their use in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability. For example, AZD2171 maleate form A was prepared by mixing AZD2171 and maleic acid in isopropanol.

IT 857036-77-2P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal forms of AZD2171 maleate used as antiangiogenic agents)

RN 857036-77-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



IT 288383-20-0, AZD2171
RL: RCT (Reactant); RACT (Reactant or reagent)
(crystal forms of AZD2171 maleate used as antiangiogenic agents)
RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:48:53 ON 09 JUN 2009)

FILE 'REGISTRY' ENTERED AT 11:48:59 ON 09 JUN 2009
L1 STRUCTURE UPLOADED
L2 18 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:49:35 ON 09 JUN 2009
L3 93 S L2

```
L4            2 S L3 AND MALEATE

=> s l3 and salt?
      1334974 SALT?
L5           21 L3 AND SALT?

=> s l5 not l4
L6           19 L5 NOT L4

=> d l6 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 19 ANSWERS - CONTINUE? Y/(N):y

L6   ANSWER 1 OF 19  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:337108  CAPLUS
DOCUMENT NUMBER:          150:352187
TITLE:                    Quinazoline derivatives as VEGFR inhibitors, their
                          preparation, pharmaceutical compositions, and use in
                          the treatment of cell proliferative diseases
INVENTOR(S):              Qian, Changgeng; Cai, Xiong; Zhai, Haixiao
PATENT ASSIGNEE(S):       Curis, Inc., USA
SOURCE:                   PCT Int. Appl., 90pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2009036055        A1    20090319    WO 2008-US75844        20080910
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     US 20090076044       A1    20090319    US 2008-207994         20080910
PRIORITY APPLN. INFO.:                     US 2007-971030P     P  20070910
                                           US 2008-35281P      P  20080310
OTHER SOURCE(S):          MARPAT 150:352187
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB   The invention relates to quinazolines of formula I, which are inhibitors
     of vascular endothelial growth factor receptors (VEGFR) and may also be
     inhibitors of histone deacetylases (HDAC). In compds. I, X1, X2, and X3
     are independently N or (un)substituted C; V, W, and Z are independently
     (un)substituted C, (un)substituted N, O, or S; Y is (un)substituted N, O,
     S, S(O), S(O)2, or (un)substituted alkylene; R1 is H, halo, hydroxy,
     amino, cyano, nitro, (un)substituted alkyl, arylalkyl, etc.; L is a
```

linker; and R2 is hydroxycarbamoyl, hydroxythiocarbamoyl, hydroxyureido, hydroxythioureido, cycloalkyl, heterocyclyl, etc.; including stereoisomers, salts, prodrugs, and solvates thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of cell proliferative diseases. Monobenzylation of Et 3,4-dihydroxybenzoate followed by substitution of Et 7-bromoheptanoate and nitration gave benzoate II, which was reduced to the amine, cyclized with formamide, and chlorinated resulting in the formation of chloroquinazoline III. Substitution of 1,2,3-trifluoro-4-nitrobenzene with deprotonated Et acetoacetate followed by decarboxylation, substitution with ammonia, and hydrogenating heterocyclization formed aminoindole IV, which underwent substitution of chloroquinazoline III, debenzylation, substitution of 1-(3-chloropropyl)pyrrolidine, and amidation with hydroxylamine to give quinazoline V. Most compds. of the invention express IC50 values below 0.1 μM for VEGFR2 inhibition, and four compds., e.g., V, also express IC50 values below 0.1 μM for HDAC inhibition.

IT 1021360-71-3P 1021360-72-4P 1021360-73-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazoline derivs. as VEGFR inhibitors for use in treatment of cell proliferative diseases)

RN 1021360-71-3 CAPLUS
CN Pentanamide, 5-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-N-hydroxy- (CA INDEX NAME)



RN 1021360-72-4 CAPLUS
CN Hexanamide, 6-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-N-hydroxy- (CA INDEX NAME)



RN 1021360-73-5 CAPLUS
CN Heptanamide, 7-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-N-hydroxy- (CA INDEX NAME)



IT 1133461-77-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazoline derivs. as VEGFR inhibitors for use in treatment of cell proliferative diseases)
RN 1133461-77-4 CAPLUS
CN Hexanoic acid, 6-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:139918 CAPLUS
DOCUMENT NUMBER: 150:183373
TITLE: A morpholinyl anthracycline derivative combined with protein kinase inhibitors for treatment of tumors
INVENTOR(S): Geroni, Maria Cristina; Valota, Olga; Ballinari, Dario; Marsiglio, Aurelio
PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy
SOURCE: PCT Int. Appl., 14pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009016072	A2	20090205	WO 2008-EP59621	20080723
WO 2009016072	A3	20090522		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,

PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-113731 A 20070802

AB The present invention provides the combined use of (i) a morpholinyl anthracycline derivative, i.e., nemorubicin or a pharmaceutically acceptable salt thereof, such as nemorubicin hydrochloride, and (ii) a protein kinase (PK) inhibitor, in the treatment of tumors and other proliferative disorders. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis. Kits comprising, in a suitable container mean, a morpholinyl anthracycline derivative and a protein kinase inhibitor for simultaneous, sep. or sequential use in antitumor therapy are also described. Thus, the cytotoxic effect of nemorubicin in combination with protein kinase inhibitor sorafenib was evaluated in vitro using human hepatocellular carcinoma cell line Hep-G2 and human mammary carcinoma cell line MCF-7. The combination resulted in a synergistic antitumor effect in both cell lines.

IT 857036-77-2, Recentin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(morpholinyl anthracycline derivative combined with protein kinase inhibitors for treatment of tumors and other proliferative disorders)

RN 857036-77-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.

L6 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:25215 CAPLUS
DOCUMENT NUMBER: 150:119716
TITLE: Anti-insulin-like growth factor 1 receptor therapy
INVENTOR(S): Wang, Yan; Pachter, Jonathan A.; Hailey, Judith Anne; Brams, Peter; Williams, Denise; Srinivasan, Mohan; Feingersh, Mary Diane
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 129pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009005673	A1	20090108	WO 2008-US7920	20080625
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2007-946803P P 20070628

AB The authors disclose the preparation and functional characterization of human antibodies to the type 1 insulin-like growth factor receptor. In one example, the growth of a human neuroblastoma was shown to be inhibited by an anti-IGF1R antibody in a xenograft model.

IT 288383-20-0, Azd 2171
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in combination therapy with anti-IGF1R antibodies)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1248933 CAPLUS
DOCUMENT NUMBER: 149:448428
TITLE: Preparation and use of quinazoline derivative for treatment of cancer
INVENTOR(S): Laughlin, Mark; Anderson, Mark B.; Willardsen, Adam; Pleiman, Chris
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA
SOURCE: PCT Int. Appl., 24pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008124826	A1	20081016	WO 2008-US59910	20080410

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-910944P P 20070410
OTHER SOURCE(S): CASREACT 149:448428
AB This document discloses the use of a compound for the manufacture of a medicament useful in treating cancer in a mammal in need of such treatment, comprising administering to the mammal an effective amount of N-(4-methoxyphenyl)-N,2-dimethyl-4-quinazolinamine hydrochloride (I), or a pharmaceutically acceptable salt or solvate thereof, and an effective amount of one or more chemotherapeutic agents chosen from antiangiogenic agents and cytotoxic agents. I was prepared in a 2-step process from 2-methyl-4(3H)-quinazolinone. The vascular disruption effect of I was demonstrated in mice. I was tested in a phase I clin. trial. Formulations are given.
IT 288383-20-0, AZD2171
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(in combination therapy; preparation and use of quinazoline derivative for treatment of cancer)
RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:881222 CAPLUS
DOCUMENT NUMBER: 149:191984
TITLE: Treatment of cancers having resistance to chemotherapeutic agents
INVENTOR(S): Wilhelm, Scott; Gedrich, Richard W.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008089388	A2	20080724	WO 2008-US51405	20080118
WO 2008089388	A3	20081231		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2007-885731P P 20070119
AB The present invention provides compns. and methods for treating cancer with DAST, 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide, including all polymorphs, hydrates, pharmaceutically acceptable salts, metabolites, prodrugs, solvates or combinations thereof. Any cancer can be treated, including cancers that have acquired resistance to another therapeutic agent, such as tyrosine kinase inhibitors. DAST

can also be used to treat cancers which have become refractory to other chemotherapeutic agents.

IT 288383-20-0, AZD2171 288383-20-0D, AZD2171, analogs and derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(resistance to; treatment of cancers with acquired resistance to tyrosine kinase inhibitors using chloro-3-trifluoromethylphenylureido-3-fluorophenoxypyridine-2-carboxylic acid methylamide)

RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



L6 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2008:796822 CAPLUS
DOCUMENT NUMBER:	149:128848
TITLE:	Preparation of 5-cyano-4-(pyrrolo[2,3-b]pyridin-3-yl)pyrimidines as polo-like kinase (PLK) inhibitors.
INVENTOR(S):	Mortimore, Michael; Young, Stephen Clinton; Everitt, Simon Robert Lorrie; Knegtel, Ronald; Pinder, Joanne Louise; Rutherford, Alistair Peter; Durrant, Steven; Brenchley, Guy; Charrier, Jean Damien; O'Donnell, Michael
PATENT ASSIGNEE(S):	Vertex Pharmaceuticals Incorporated, USA
SOURCE:	PCT Int. Appl., 191pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008079346	A1	20080703	WO 2007-US26190	20071221

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
US 2006-876307P P 20061221
US 2007-922291P P 20070406
US 2007-947707P P 20070703
US 2007-989014P P 20071119

OTHER SOURCE(S): MARPAT 149:128848

GI



I

AB Title compds. [I; R1 = H, halo, (substituted) aliphatyl, aliphatyloxy; R2 = NR4R5, OR6, SR6, etc.; R4 = H, (substituted) aliphatyl; R5 = (substituted) aliphatyl, mono- or bicyclyl; R4R5 = atoms to form (substituted) mono- or bicyclyl; R6 = H, (substituted) alkyl, aryl(alkyl), heteroaryl(alkyl)], were prepared Thus, 2-methylsulfonyl-4-(1-tosyl-5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile (preparation given) was microwaved with PhCH2NH2 and diisopropylamine in THF at 100° for 10 min. to give a residue which was stirred with LiOH in THF/H2O for 1 h to give 36% 2-benzylamino-4-(5-trifluoromethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidine-5-carbonitrile. I inhibited PLK1 with Ki in the range of <3 nM to >40 nM.

IT 288383-20-0, AZD 2171
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of cyanopyrrolopyridinylpyrimidines as polo-like kinase inhibitors)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:380887 CAPLUS
DOCUMENT NUMBER: 148:394375
TITLE: Method for treating cancer harboring EGFR mutations
INVENTOR(S): Solca, Flavio
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 60pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008034776	A1	20080327	WO 2007-EP59735	20070914
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007299080	A1	20080327	AU 2007-299080	20070914
CA 2663599	A1	20080327	CA 2007-2663599	20070914
PRIORITY APPLN. INFO.:			EP 2006-120856 A	20060918
			EP 2007-101505 A	20070131
			WO 2007-EP59735 W	20070914

AB The present invention relates to a method of treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline), to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumor resection by surgery, and

to the use of a BIBW2992 for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harboring mutations of EGFR in the tumor.

IT 288383-20-0, AZD-2171
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treating cancer harboring EGFR mutations using BIBW2992 in combination with other chemotherapeutic agents)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:353001 CAPLUS
DOCUMENT NUMBER: 148:355828
TITLE: Multi-functional small molecules as anti-proliferative agents and their preparation
INVENTOR(S): Cai, Xiong; Qian, Changgeng; Gould, Stephen; Zhai, Haixiao
PATENT ASSIGNEE(S): Curis, Inc., USA
SOURCE: PCT Int. Appl., 494pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008033747	A2	20080320	WO 2007-US77971	20070910
WO 2008033747	A9	20080724		
WO 2008033747	A3	20081204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2007296744	A1	20080320	AU 2007-296744	20070910

US 20080221132 A1 20080911 US 2007-852458 20070910
EP 2061772 A2 20090527 EP 2007-842112 20070910
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.: US 2006-843590P P 20060911
US 2007-895889P P 20070320
WO 2007-US77971 W 20070910
OTHER SOURCE(S): MARPAT 148:355828

GI



A—B—C I II

AB The invention relates to the compns., methods, and applications of an approach to selective inhibition of several cellular or mol. targets with a single small mol. More specifically, the present invention relates to multi-functional small mols. of formula I wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or mol. pathway involved in aberrant cell proliferation, differentiation or survival. Compds. of formula I wherein A is a pharmacophore of an anticancer agent capable of inhibiting at least one cellular or mol. pathway involved in the aberrant cell proliferation, differentiation or survival; B is a linker; C is a zinc-binding moiety; and their geometrical isomers, enantiomers, diastereoisomers, racemates, pharmaceutically acceptable salts, prodrugs and solvates thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compds. were evaluated for their antiproliferative activity (some data given).

IT 1021360-71-3P 1021360-72-4P 1021360-73-5P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRPH (Prophetic); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prophetic starting material; preparation of multi-functional small mols. as antiproliferative agents)

RN 1021360-71-3 CAPLUS

CN Pentanamide, 5-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-N-hydroxy- (CA INDEX NAME)



RN 1021360-72-4 CAPLUS
CN Hexanamide, 6-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-N-hydroxy- (CA INDEX NAME)



RN 1021360-73-5 CAPLUS
CN Heptanamide, 7-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-7-[3-(1-pyrrolidinyl)propoxy]-6-quinazolinyl]oxy]-N-hydroxy- (CA INDEX NAME)



L6 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:703004 CAPLUS
DOCUMENT NUMBER: 147:64518
TITLE: AZD2171 plus pemetrexed for treatment of cancer and angiogenesis-related disorders
INVENTOR(S): Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 26pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2007071970	A2	20070628	WO 2006-GB4768	20061219
WO 2007071970	A3	20070809		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006328201	A1	20070628	AU 2006-328201	20061219
CA 2631676	A1	20070628	CA 2006-2631676	20061219
EP 1965801	A2	20080910	EP 2006-820574	20061219
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
JP 2009520787	T	20090528	JP 2008-546594	20061219
NO 2008002566	A	20080731	NO 2008-2566	20080602
MX 2008007986	A	20080707	MX 2008-7986	20080619
US 20080306094	A1	20081211	US 2008-158266	20080619
CN 101346142	A	20090114	CN 2006-80048876	20080623
KR 2008077678	A	20080825	KR 2008-716943	20080711
PRIORITY APPLN. INFO.:			GB 2005-26132	A 20051222
			GB 2006-10708	A 20060531
			WO 2006-GB4768	W 20061219

AB The invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor, which comprises the administration of AZD2171 in combination with pemetrexed; to a pharmaceutical composition comprising AZD2171 and pemetrexed; to a combination product comprising AZD2171 and pemetrexed for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and pemetrexed; to the use of AZD2171 and pemetrexed in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation. Administration of AZD2171 with pemetrexed resulted in significantly greater inhibition of breast tumor in mice than either agent alone.

IT 288383-20-0, AZD2171 288383-20-0D, AZD2171, salt
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(kit; AZD2171 plus pemetrexed for treatment of cancer and angiogenesis-related disorders)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



L6 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:585496 CAPLUS
DOCUMENT NUMBER: 147:16554
TITLE: Pharmaceutical compositions containing AZD2171 and fillers with high surface area excluding lactose
INVENTOR(S): Simpson, David Bradley Brook; Cahill, Julie Kay; Richer, Sebastien; Cumberbatch, Daren James; Holt, David John; Swain, Elizabeth Anne
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 58pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007060402	A1	20070531	WO 2006-GB4320	20061121

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2006318946	A1	20070531	AU 2006-318946		20061121
CA 2628917	A1	20070531	CA 2006-2628917		20061121
EP 1954247	A1	20080813	EP 2006-808603		20061121
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS					
JP 2009516726	T	20090423	JP 2008-541808		20061121
NO 2008002097	A	20080818	NO 2008-2097		20080506
IN 2008DN03842	A	20090320	IN 2008-DN3842		20080506
MX 2008006618	A	20080530	MX 2008-6618		20080522
CN 101312715	A	20081126	CN 2006-80043657		20080522
US 20090028943	A1	20090129	US 2008-94702		20080522
KR 2008070056	A	20080729	KR 2008-713620		20080605
PRIORITY APPLN. INFO.:			GB 2005-23810	A	20051123
			WO 2006-GB4320	W	20061121

AB Disclosed is pharmaceutical compns. comprising AZD2171 or a pharmaceutically acceptable salt thereof, including pharmaceutical compns. comprising AZD2171 or a pharmaceutically acceptable salt and a plastic filler with a high surface area, excluding lactose.

IT 288383-20-0, AZD2171 857036-77-2
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. containing AZD2171 and fillers with high surface area excluding lactose)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 857036-77-2 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:537782 CAPLUS
DOCUMENT NUMBER: 146:514717
TITLE: Combination treatment of cancer comprising EGFR/HER2 inhibitors
INVENTOR(S): Solca, Flavio; Amelsberg, Andree; Stehle, Gerd; Van Meel, Jacobus C. A.; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007054551	A1	20070518	WO 2006-EP68314	20061109

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

CA 2629249 A1 20070518 CA 2006-2629249 20061109
EP 1948180 A1 20080730 EP 2006-819380 20061109
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2009515852 T 20090416 JP 2008-539441 20061109
PRIORITY APPLN. INFO.: EP 2005-110669 A 20051111
WO 2006-EP68314 W 20061109
OTHER SOURCE(S): MARPAT 146:514717
GI



I

AB The invention discloses a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amts. of (1) a compound I (Ra = benzyl, 1-phenylethyl, 3-chloro-4-fluorophenyl; Rb = H, C1-4 alkyl; Rc = cyclopropylmethoxy, cyclobutoxy, etc.; Rd = dimethylamino, N-cyclopropyl-N-methylamino, etc.); and (2) at least a further chemotherapeutic agent; optionally in combination with radiotherapy, radioimmunotherapy and/or tumor resection by surgery. The invention further discloses corresponding medicaments and the preparation thereof.
IT 288383-20-0, AZD-2171
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(EGFR/HER2 inhibitor combination treatment for cancer)
RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:150229 CAPLUS
DOCUMENT NUMBER: 146:221063
TITLE: Method for assaying anti-tumor effect of angiogenesis inhibitor

INVENTOR(S): Uenaka, Toshimitsu; Yamamoto, Yuji; Matsui, Junji
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 147pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015578	A1	20070208	WO 2006-JP315698	20060802
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1925676	A1	20080528	EP 2006-768437	20060802
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: JP 2005-224173 A 20050802
JP 2006-164700 A 20060614
WO 2006-JP315698 W 20060802

OTHER SOURCE(S): MARPAT 146:221063

AB Disclosed is a method for predicting the anti-tumor effect of an angiogenesis inhibitor. The method comprises evaluating the EGF-dependence property of an angiogenesis inhibitor with respect to proliferation and/or survival of tumor cells, and using the evaluated EGF-dependence property as a measure. The anti-tumor effect of an angiogenesis inhibitor correlates with the EGF-dependency property of the inhibitor with respect to proliferation and/or survival of tumor cells. Therefore, an angiogenesis inhibitor is capable of exerting an excellent anti-tumor effect by using it in combination with a substance having an EGF inhibitory effect.

IT 288383-20-0, AZD 2171
RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(method for assaying anti-tumor effect of angiogenesis inhibitor by evaluating EGF-dependency)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:144036 CAPLUS
DOCUMENT NUMBER: 146:221062
TITLE: Method for predicting antitumor efficacy of angiogenesis inhibitor
INVENTOR(S): Matsui, Junji; Semba, Taro
PATENT ASSIGNEE(S): Eisai R & D Management Co., Ltd., Japan
SOURCE: PCT Int. Appl., 104pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015569	A1	20070208	WO 2006-JP315563	20060801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1925941	A1	20080528	EP 2006-782407	20060801
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				

PRIORITY APPLN. INFO.: JP 2005-223440 A 20050801
WO 2006-JP315563 W 20060801
OTHER SOURCE(S): MARPAT 146:221062

AB A method for predicting the antitumor efficacy of an angiogenesis inhibitor is provided, which comprises measuring the number of blood vessels surrounded by pericytes in tumor, and using the measurement value as a measure for the anti-tumor effect.

IT 288383-20-0
RL: ANT (Analyte); BSU (Biological study, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(method for predicting antitumor efficacy of angiogenesis inhibitor)
RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:33362 CAPLUS
DOCUMENT NUMBER: 146:115014
TITLE: Gemcitabine-AZD2171 combination antiangiogenic and/or vascular permeability-reducing therapy, especially for the treatment of cancer
INVENTOR(S): Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 28pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007003933	A2	20070111	WO 2006-GB2462	20060703
WO 2007003933	A3	20071227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006264620	A1	20070111	AU 2006-264620	20060703
CA 2614002	A1	20070111	CA 2006-2614002	20060703
EP 1901754	A2	20080326	EP 2006-755701	20060703
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2009500384	T	20090108	JP 2008-519988	20060703
MX 2007016497	A	20080307	MX 2007-16497	20071219
NO 2007006657	A	20080403	NO 2007-6657	20071228
CN 101217966	A	20080709	CN 2006-80024579	20080104
IN 2008DN00530	A	20080711	IN 2008-DN530	20080118

KR 2008031029 A 20080407 KR 2008-702092 20080125
PRIORITY APPLN. INFO.: GB 2005-13778 A 20050706
GB 2005-14347 A 20050713
WO 2006-GB2462 W 20060703

AB The invention discloses a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal, e.g. a human, which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor, which comprises the administration of AZD2171 in combination with gemcitabine. The invention also discloses a pharmaceutical composition comprising AZD2171 and gemcitabine; a combination product comprising AZD2171 and gemcitabine for use in a method of treatment of a human or animal body by therapy; a kit comprising AZD2171 and gemcitabine; the use of AZD2171 and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation.

IT 288383-20-0, AZD2171 288383-20-0D, AZD2171, salts 918475-54-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(gemcitabine-AZD2171 combination antiangiogenic and/or vascular permeability-reducing therapy, especially for treatment of cancer)

RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 918475-54-4 CAPLUS
CN Cytidine, 2'-deoxy-2',2'-difluoro-, mixt. with 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 95058-81-4
CMF C9 H11 F2 N3 O4

Absolute stereochemistry. Rotation (+).



L6 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:167588 CAPLUS
DOCUMENT NUMBER: 144:254148
TITLE: Aminopteridinones as anticancer agents, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US	20060058311	A1	20060316	US 2005-189540	20050726
AU	2005274384	A1	20060223	AU 2005-274384	20050809
CA	2576269	A1	20060223	CA 2005-2576269	20050809
EP	1827441	A1	20070905	EP 2005-770228	20050809
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
CN	101039673	A	20070919	CN 2005-80035272	20050809
JP	2008509948	T	20080403	JP 2007-526349	20050809
BR	2005014357	A	20080610	BR 2005-14357	20050809
ZA	2007000280	A	20080528	ZA 2007-280	20070110
IN	2007DN00888	A	20070803	IN 2007-DN888	20070202
MX	2007001853	A	20070328	MX 2007-1853	20070214
KR	2007050478	A	20070515	KR 2007-705955	20070314

PRIORITY APPLN. INFO.:	EP 2004-19361	A	20040814
	EP 2004-19448	A	20040817
	WO 2005-EP8623	W	20050809

OTHER SOURCE(S): CASREACT 144:254148; MARPAT 144:254148

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to a group of aminopteridinones I, which are useful for the treatment of diseases which involve cell proliferation. In compds. I, R1 and R2 are independently selected from H and (un)substituted C1-6 alkyl, or R1 and R2 together form a 2- to 5-membered alkylene bridge, optionally containing 1 or 2 heteroatoms; R3 is (un)substituted C1-12 alkyl, C2-12 alkenyl, C2-12 alkynyl, C6-14 aryl, etc.; R4 is H, OH, CN, halo, (un)substituted amino, (un)substituted C1-6 alkyl, C1-5 alkoxy, etc.; L is (un)substituted C2-10 alkylene, (un)substituted C2-10 alkenylene, (un)substituted C6-14 arylene, etc.; R5 is (un)substituted morpholinyl, (un)substituted piperidinyl, (un)substituted piperazinyl, (un)substituted piperazinylcarbonyl, (un)substituted pyrrolidinyl, (un)substituted thiomorpholinyl, etc.; n is 0 or 1; and m is 1 or 2; including tautomers, stereoisomers, salts, solvates, polymorphs, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, at least one other therapeutic agent, optionally with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. for the treatment of diseases which involve cell proliferation, migration or apoptosis of cancer cells, or angiogenesis. Esterification of (R)-2-aminobutyric acid and reductive condensation with cyclopentanone gave cyclopentylamine II, which underwent regioselective substitution of 2,4-dichloro-5-nitropyrimidine and reductive heterocyclization to form pteridinone III. N-Methylation of III followed by substitution with 4-amino-3-methoxybenzoic acid and amidation with 1-methyl-4-aminopiperidine resulted in the formation of aminopteridinone IV. A combination of suboptimal doses of irinotecan and compound IV shows an additive/synergistic effect in a human colon carcinoma model and is well tolerated. Meanwhile, compound IV acts at least

additively with docetaxel in a human non-small cell lung carcinoma model and not antagonistically with gemcitabine in a human adenocarcinoma model.

IT 288383-20-0, AZD-2171
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopteridinones for use in combination therapy for treatment of cell proliferative diseases)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1075607 CAPLUS
DOCUMENT NUMBER: 143:339615
TITLE: AZD2171 in combination with 5-FU and/or CPT-11 for the treatment of cancer
INVENTOR(S): Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092303	A2	20051006	WO 2005-GB1080	20050322
WO 2005092303	A3	20061102		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005225193	A1	20051006	AU 2005-225193	20050322
AU 2005225193	B2	20081009		
CA 2610628	A1	20051006	CA 2005-2610628	20050322
EP 1729808	A2	20061213	EP 2005-729381	20050322
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

CN	1964742	A	20070516	CN	2005-80009218		20050322
BR	2005008982	A	20070828	BR	2005-8982		20050322
JP	2007530518	T	20071101	JP	2007-504467		20050322
ZA	2006007555	A	20080528	ZA	2006-7555		20060908
MX	2006010758	A	20061215	MX	2006-10758		20060920
US	20080125447	A1	20080529	US	2006-594233		20060925
NO	2006004755	A	20061020	NO	2006-4755		20061020
KR	2006130763	A	20061219	KR	2006-721774		20061020
PRIORITY APPLN. INFO.:				GB	2004-6446	A	20040323
				WO	2005-GB1080	W	20050322

AB The invention discloses a method for the production of an antiangiogenic and/or vascular permeability-reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor, which comprises the administration of AZD2171 in combination with 5-FU, CPT-11 or 5-FU and CPT-11. The invention also discloses a pharmaceutical composition comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11; a combination product comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11 for use in a method of treatment of a human or animal body by therapy; a kit comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11; the use of AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability-reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation.

IT 288383-20-0, AZD2171 288383-20-0D, AZD2171, salts 857036-77-2 865756-24-7 865756-25-8 865756-26-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(AZD2171 in combination with 5-FU and/or CPT-11 for treatment of cancer)

RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 857036-77-2 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 865756-24-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-, mixt. with 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline (9CI) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 51-21-8
CMF C4 H3 F N2 O2

RN 865756-25-8 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride, mixt. with 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline (9CI) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 100286-90-6
CMF C33 H38 N4 O6 . Cl H

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A

● HCl

RN 865756-26-9 CAPLUS
CN [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride, mixt. with 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline and 5-fluoro-2,4(1H,3H)-pyrimidinedione (9CI) (CA INDEX NAME)

CM 1

CRN 288383-20-0
CMF C25 H27 F N4 O3



CM 2

CRN 100286-90-6
CMF C33 H38 N4 O6 . Cl H

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A

● HCl

CM 3

CRN 51-21-8
CMF C4 H3 F N2 O2



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:99470 CAPLUS
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722
WO 2005009961	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004259760	A1	20050203	AU 2004-259760	20040722
CA 2532865	A1	20050203	CA 2004-2532865	20040722
US 20050038080	A1	20050217	US 2004-895985	20040722
EP 1663978	A2	20060607	EP 2004-786091	20040722
EP 1663978	B1	20071128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004012219	A	20060822	BR 2004-12219	20040722
CN 1856469	A	20061101	CN 2004-80021091	20040722
JP 2006528196	T	20061214	JP 2006-521221	20040722
ES 2297490	T3	20080501	ES 2004-786091	20040722
ZA 2006000609	A	20070530	ZA 2006-609	20060120
KR 2006052866	A	20060519	KR 2006-701558	20060123
MX 2006000860	A	20060720	MX 2006-860	20060123
IN 2006DN00402	A	20070824	IN 2006-DN402	20060123

PRIORITY APPLN. INFO.:
US 2003-489102P P 20030723
US 2004-540326P P 20040202
WO 2004-US23500 W 20040722

OTHER SOURCE(S): CASREACT 142:197889
GI



I

AB Title compound I is prepared I and salts thereof is prepared in several steps from 3-fluoro-4-nitrophenol, 4-chloro-N-methylpyridine-2-carboxamide and 4-chloro-3-(trifluoromethyl)phenylisocyanate. I inhibits PDGFR tyrosine kinase with IC50 = 83 nM. I is useful for the treatment of, e.g., inflammation and as an antiproliferative agent.

IT 288383-20-0, AZD 2171
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)
RN 288383-20-0 CAPLUS
CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:965067 CAPLUS
DOCUMENT NUMBER: 141:406039
TITLE: Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis
INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin Friedrich; Baum, Anke; Munzert, Gerd; Van Meel, Jacobus C. A.
PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	A1	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
JP 2006524634	T	20061102	JP 2006-500099	20040424
MX 2005011656	A	20051215	MX 2005-11656	20051028
NO 2005005605	A	20051128	NO 2005-5605	20051128
PRIORITY APPLN. INFO.:			EP 2003-9587	A 20030429
			EP 2004-508	A 20040113
			EP 2004-1171	A 20040121
			WO 2004-EP4363	W 20040424

AB The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amts. of specific active compds. and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compds. and/or radiotherapy for the manufacture of corresponding pharmaceutical combination prepns. The pharmaceutical combination can include selected protein tyrosine kinase receptor antagonists and further chemotherapeutic or naturally occurring semisynthetic or synthetic agents.

IT 288383-20-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug combinations for diseases involving cell proliferation and migration or apoptosis or angiogenesis including protein tyrosine kinase receptor antagonists and radiotherapy)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	2000:573671 CAPLUS
DOCUMENT NUMBER:	133:177183
TITLE:	Preparation of quinazoline derivatives as angiogenesis inhibitors
INVENTOR(S):	Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren
PATENT ASSIGNEE(S):	Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.
SOURCE:	PCT Int. Appl., 346 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362715	A1	20000817	CA 2000-2362715	20000208
EP 1154774	A1	20011121	EP 2000-902730	20000208
EP 1154774	B1	20050622		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200102314	T2	20020121	TR 2001-2314	20000208
BR 2000008128	A	20020213	BR 2000-8128	20000208
HU 2001004964	A2	20020429	HU 2001-4964	20000208
HU 2001004964	A3	20030228		
JP 2002536414	T	20021029	JP 2000-598164	20000208
JP 3893026	B2	20070314		
EE 200100409	A	20021216	EE 2001-409	20000208
AU 763618	B2	20030731	AU 2000-24475	20000208
NZ 513204	A	20040430	NZ 2000-513204	20000208
CN 1167422	C	20040922	CN 2000-806085	20000208
CN 1597667	A	20050323	CN 2004-10058982	20000208
CN 100360505	C	20080109		
TR 200500745	T2	20050523	TR 2005-745	20000208
NZ 530832	A	20050527	NZ 2000-530832	20000208
EP 1553097	A1	20050713	EP 2005-4285	20000208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 298237	T	20050715	AT 2000-902730	20000208
RU 2262935	C2	20051027	RU 2001-124816	20000208
ES 2242596	T3	20051116	ES 2000-902730	20000208
IL 144745	A	20081103	IL 2000-144745	20000208
EP 2050744	A1	20090422	EP 2008-168638	20000208
R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, AL, LT, LV, MK, RO, SI				
IN 2000DE00115	A	20050311	IN 2000-DE115	20000211
IN 2001MN00893	A	20070525	IN 2001-MN893	20010726
ZA 2001006340	A	20021101	ZA 2001-6340	20010801
NO 2001003882	A	20011009	NO 2001-3882	20010809
NO 321604	B1	20060612		
MX 2001008182	A	20030820	MX 2001-8182	20010810
KR 838617	B1	20080616	KR 2001-710133	20010810
HK 1041212	A1	20051202	HK 2002-102781	20020412
US 7074800	B1	20060711	US 2002-913020	20020506
NO 2005002773	A	20011009	NO 2005-2773	20050608
US 20060004017	A1	20060105	US 2005-169122	20050629
HK 1076104	A1	20081031	HK 2005-108262	20050921
JP 2006273860	A	20061012	JP 2006-129249	20060508
KR 2008015482	A	20080219	KR 2007-731001	20071231

PRIORITY APPLN. INFO.:		
	EP 1999-400305	A 19990210
	EP 2000-902730	A3 20000208

EP 2005-4285	A3	20000208
JP 2000-598164	A3	20000208
WO 2000-GB373	W	20000208
KR 2001-710133	A3	20010810
US 2002-913020	A3	20020506

OTHER SOURCE(S): MARPAT 133:177183

GI



I



II

AB The title compds. (I) [wherein A = an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic ring optionally containing 1-3 O, N, and/or S heteroatoms; Z = O, NH, S, CH2, or a bond; n = 0-5; m = 0-3; R2 = H, OH, halo, CN, NO2, CF3, alkyl(sulfanyl), alkoxy, NR3N4, or R5X1; R3 and R4 = independently H or alkyl; X1 = a bond, O, CH2, OC(O), CO, S, SO, SO2, NR6CO, CONR7, SO2R8, NR9SO2, or NR10; R5 = H or (un)substituted alkyl, alkenyl, alkynyl, or heterocyclyl, etc.; R6-R10 = independently H or (alkoxy)alkyl] were prepared for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. For instance, II was synthesized in a 9-step sequence starting with the cyclization of 2-amino-4-benzyloxy-5-methoxybenzamide using Gold's reagent in dioxane to form 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (84%). I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis (no data).

IT 288383-20-0P, 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline 288383-25-5P, (R)-7-[2-Hydroxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(angiogenesis inhibitor; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)

RN 288383-20-0 CAPLUS

CN Quinazoline, 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]- (CA INDEX NAME)



RN 288383-25-5 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 288386-37-8P, (R)-7-[2-Acetoxy-3-(pyrrolidin-1-yl)propoxy]-4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxyquinazoline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolines as angiogenesis inhibitors by cyclization of 2-aminobenzamides and subsequent derivatization)
RN 288386-37-8 CAPLUS
CN 1-Pyrrolidineethanol, α-[[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-quinazolinyl]oxy]methyl]-, 1-acetate, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:48:53 ON 09 JUN 2009)

FILE 'REGISTRY' ENTERED AT 11:48:59 ON 09 JUN 2009
L1 STRUCTURE UPLOADED
L2 18 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:49:35 ON 09 JUN 2009
L3 93 S L2
L4 2 S L3 AND MALEATE
L5 21 S L3 AND SALT?
L6 19 S L5 NOT L4

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST		XXXXXXXXXXXXXXXXXXX
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-17.22	-17.22

STN INTERNATIONAL LOGOFF AT 11:52:04 ON 09 JUN 2009